Zydus Gets Health Canada Nod for Mesalamine Suppository

Health Canada has issued a Notice of Compliance (NOC) to Zydus Lifesciences Limited for their generic 1000 mg mesalamine suppositories.

Mildly to moderately active ulcerative proctitis can be treated with mesalamine suppositories.

The Zydus Lifesciences Ltd. plant at Changodar, Ahmedabad, Gujarat, India, will produce ZDS-Mesalamine suppositories. According to IQVIA MAT June 2025 data, mesalamine suppositories sold CAD 4.86 million annually in Canada.

Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited, is a multinational pharmaceutical company based in India, and is headquartered in Ahmedabad. The company mainly manufacturers generic medicines and was ranked 100th on the Fortune India 500 list in 2020.

Also Read: Novartis to Acquire Avidity Biosciences in $12 Billion Deal

Zydus Cadila has twenty-five pharmaceutical manufacturing plants located in India and executes research, manufactures and sells pharmaceutical products, diagnostics, herbal products, dermatological products, and over-the-counter products. Since late 2015, the company has been producing generic medicines to treat hepatitis C since it entered a voluntary licensing arrangement with Gilead.

The company produces APIs in India at three facilities,  Ankleshwar, Vadodara, and Patalganga.

Zydus' innovation program is powered by 1,400 researchers at 19 facilities working on differentiated therapies for a better tomorrow. The group is constantly exploring new ideas and innovations, in areas ranging from NCEs to vaccines, biosimilars, and niche technologies.